[
    [
        {
            "time": "2019-06-17",
            "original_text": "Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Acquisition",
                    "Array BioPharma",
                    "Pay Off",
                    "Soon"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-17",
            "original_text": "Pfizer Expands in Cancer With $10.6 Billion Deal for Array",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Cancer",
                    "$10.6 Billion",
                    "Deal",
                    "Array"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "cancer"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer Expands in Cancer With $10.6 Billion Deal for Array",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-06-17",
            "original_text": "Pfizer's $11 Billion Cancer-Drug Deal Takes Pricey Path to Growth",
            "features": {
                "keywords": [
                    "Pfizer",
                    "$11 Billion",
                    "Cancer-Drug",
                    "Deal",
                    "Growth"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "cancer"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer's $11 Billion Cancer-Drug Deal Takes Pricey Path to Growth",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06-17",
            "original_text": "Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "High-Growth",
                    "Dividend",
                    "Stock",
                    "Great Choice"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice",
                "Correlation": 2,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]